Myelofibrosis is a disorder of the bone marrow in which the marrow is replaced by fibrous scar tissue.
Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that develop into all of your blood cells. Your blood is made of:
- Red blood cells (which carry oxygen to your tissues)
- White blood cells (which fight infection)
- Platelets (which help your blood clot)
When the bone marrow is scarred, it cannot make enough blood cells. Anemia, bleeding problems, and a higher risk for infections may occur.
As a result, the liver and spleen try to make some of these blood cells. This causes these organs to swell.
The cause of myelofibrosis is often unknown. There are no known risk factors. When it occurs, it often develops slowly in people over age 50. Women and men are equally affected. There is an increased occurrence of this condition in Ashkenazi Jews.
Blood and bone marrow cancers, such as myelodysplastic syndrome, leukemia, and lymphoma, may also cause bone marrow scarring. This is called secondary myelofibrosis.
Symptoms may include any of the following:
Exams and Tests
The health care provider will perform a physical exam and ask about the symptoms.
Tests that may be done include:
Bone marrow or stem cell transplant may improve symptoms, and may cure the disease. This treatment is usually considered for younger people.
Other treatment may involve:
As the disease worsens, the bone marrow slowly stops working. Low platelet count leads to easy bleeding. Spleen swelling may get worse along with anemia.
Survival of people with primary myelofibrosis is about 5 years. But some people survive for decades.
Complications may include:
- Development of acute myelogenous leukemia
- Blood clots
- Liver failure
When to Contact a Medical Professional
Make an appointment with your provider if you have symptoms of this disorder. Seek medical care right away for uncontrolled bleeding, shortness of breath, or jaundice (yellow skin and whites of the eyes) that gets worse.
Idiopathic myelofibrosis; Myeloid metaplasia; Agnogenic myeloid metaplasia; Primary myelofibrosis; Secondary myelofibrosis; Bone marrow - myelofibrosis
Gotlib J. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 157.
Long NM, Kavanagh EC. Myelofibrosis. In: Pope TL, Bloem HL, Beltran J, Morrison WB, Wilson DJ, eds. Musculoskeletal Imaging. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 76.
Mascarenhas J, Najfeld V, Kremyanskaya M, Keyzner A, Salama ME, Hoffman R. Primary myelofibrosis. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 70.
Review Date 5/27/2020
Updated by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.